Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
SNTI similar filings
- 15 Aug 22 Senti Bio Reports Second Quarter Financial Results and Business Updates
- 29 Jul 22 Departure of Directors or Certain Officers
- 19 Jul 22 Departure of Directors or Certain Officers
- 15 Jun 22 Index to Condensed Consolidated Financial Statements
- 9 Jun 22 Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits
- 7 Jun 22 Departure of Directors or Certain Officers
- 25 May 22 Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer
Filing view
External links
Exhibit 16.1
June 14, 2022
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Senti Biosciences, Inc. (formerly Dynamics Special Purpose Corp.) under Item 4.01 of its Form 8-K filed June 14, 2022. We agree with the statements concerning our Firm under Item 4.01 of such Form 8-K; we are not in a position to agree or disagree with other statements of Senti Biosciences, Inc. (formerly Dynamics Special Purpose Corp.) contained therein.
Very truly yours,
/s/ MarcumLLP
MarcumLLP